Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 398 articles:
HTML format



Single Articles


    January 2022
  1. KONDO T, Koroki K, Kanzaki H, Kobayashi K, et al
    Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma.
    PLoS One. 2022;17:e0261619.
    PubMed     Abstract available


  2. THOMAS KL, Root CL, Peterson JM
    Transgenic overexpression of CTRP3 does not prevent alcohol induced hepatic steatosis in female mice.
    PLoS One. 2022;17:e0258557.
    PubMed     Abstract available


  3. DRESSEL-BOHM S, Richter H, Kircher PR, Del Chicca F, et al
    Hypoattenuating periportal halo on CT in a patient population can occur in presence of a variety of diseases.
    PLoS One. 2022;17:e0260436.
    PubMed     Abstract available


  4. KIM KE, Sinn DH, Choi MS, Kim H, et al
    Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment.
    PLoS One. 2022;17:e0262750.
    PubMed     Abstract available


  5. ABDALLAH HMI, El Awdan SA, Abdel-Rahman RF, Farrag ARH, et al
    1,8 Cineole and Ellagic acid inhibit hepatocarcinogenesis via upregulation of MiR-122 and suppression of TGF-beta1, FSCN1, Vimentin, VEGF, and MMP-9.
    PLoS One. 2022;17:e0258998.
    PubMed     Abstract available


  6. DU Y, Cortez A, Josefsson A, Zarisfi M, et al
    Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma.
    PLoS One. 2022;17:e0261982.
    PubMed     Abstract available


  7. LIU X, Taylor SA, Gromer KD, Zhang D, et al
    Mechanisms of liver injury in high fat sugar diet fed mice that lack hepatocyte X-box binding protein 1.
    PLoS One. 2022;17:e0261789.
    PubMed     Abstract available


  8. MEIJER TS, Dieters JHN, de Leede EM, de Geus-Oei LF, et al
    Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer.
    PLoS One. 2022;17:e0261939.
    PubMed     Abstract available


  9. RADFORD-SMITH DE, Patel PJ, Irvine KM, Russell A, et al
    Depressive symptoms in non-alcoholic fatty liver disease are identified by perturbed lipid and lipoprotein metabolism.
    PLoS One. 2022;17:e0261555.
    PubMed     Abstract available


  10. BRAUNWARTH E, Schullian P, Kummann M, Reider S, et al
    Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma-Stereotactic radiofrequency ablation as a valuable addition to hepatic resection.
    PLoS One. 2022;17:e0261136.
    PubMed     Abstract available


  11. MIZUNO H, Sekine A, Suwabe T, Ikuma D, et al
    Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
    PLoS One. 2022;17:e0264065.
    PubMed     Abstract available


  12. KIM SS, Kycia I, Karski M, Ma RK, et al
    DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.
    PLoS One. 2022;17:e0263829.
    PubMed     Abstract available


  13. SANSILVESTRI MOREL P, Duvivier V, Bertin F, Provost N, et al
    Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression.
    PLoS One. 2022;17:e0263828.
    PubMed     Abstract available


  14. ASADULLAH M, Shivashankar R, Shalimar, Kandasamy D, et al
    Rural-Urban differentials in prevalence, spectrum and determinants of Non-alcoholic Fatty Liver Disease in North Indian population.
    PLoS One. 2022;17:e0263768.
    PubMed     Abstract available


  15. YAN J, Huang QY, Huang YJ, Wang CS, et al
    SPATS2 is positively activated by long noncoding RNA SNHG5 via regulating DNMT3a expression to promote hepatocellular carcinoma progression.
    PLoS One. 2022;17:e0262262.
    PubMed     Abstract available


  16. ROH JH, Lee H, Yun-Jeong B, Park CS, et al
    A nationwide survey of the association between nonalcoholic fatty liver disease and the incidence of asthma in Korean adults.
    PLoS One. 2022;17:e0262715.
    PubMed     Abstract available


  17. KANMANI P, Kim H
    Probiotics counteract the expression of hepatic profibrotic genes via the attenuation of TGF-beta/SMAD signaling and autophagy in hepatic stellate cells.
    PLoS One. 2022;17:e0262767.
    PubMed     Abstract available


  18. YAMAOKA K, Kodama K, Kawaoka T, Kosaka M, et al
    The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
    PLoS One. 2022;17:e0262675.
    PubMed     Abstract available


  19. LAI HF, Chau IY, Lei HJ, Chou SC, et al
    Postoperative fever after liver resection: Incidence, risk factors, and characteristics associated with febrile infectious complication.
    PLoS One. 2022;17:e0262113.
    PubMed     Abstract available


  20. MATSUSHIMA-NISHIWAKI R, Yamada N, Hattori Y, Hosokawa Y, et al
    SERMs (selective estrogen receptor modulator), acting as estrogen receptor beta agonists in hepatocellular carcinoma cells, inhibit the transforming growth factor-alpha-induced migration via specific inhibition of AKT signaling pathway.
    PLoS One. 2022;17:e0262485.
    PubMed     Abstract available


  21. FERNANDEZ T, Vinuela M, Vidal C, Barrera F, et al
    Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0263931.
    PubMed     Abstract available


  22. STOFFERS P, Guckenbiehl S, Welker MW, Zeuzem S, et al
    Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation.
    PLoS One. 2022;17:e0263989.
    PubMed     Abstract available


  23. SUWIMOL S, Pisit T, Anchalee A, Narisorn K, et al
    Neck circumference as a screening measure for identifying NAFLD among a group of academic employees in Bangkok, Thailand.
    PLoS One. 2022;17:e0263826.
    PubMed     Abstract available


  24. RATNASARI N, Lestari P, Renovaldi D, Raditya Ningsih J, et al
    Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients.
    PLoS One. 2022;17:e0263298.
    PubMed     Abstract available


  25. LIU L, Fu Q, Li T, Shao K, et al
    Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency.
    PLoS One. 2022;17:e0262855.
    PubMed     Abstract available


  26. YOKOYAMA K, Sakamaki A, Takahashi K, Naruse T, et al
    Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function.
    PLoS One. 2022;17:e0264459.
    PubMed     Abstract available


  27. MORISHITA A, Tadokoro T, Fujihara S, Iwama H, et al
    Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
    PLoS One. 2022;17:e0261310.
    PubMed     Abstract available


  28. ARNEY J, Gray C, Clark JA, Smith D, et al
    Prognosis conversations in advanced liver disease: A qualitative interview study with health professionals and patients.
    PLoS One. 2022;17:e0263874.
    PubMed     Abstract available


  29. MILES LF, Couture EJ, Potes C, Makar T, et al
    Preliminary experience with continuous right ventricular pressure and transesophageal echocardiography monitoring in orthotopic liver transplantation.
    PLoS One. 2022;17:e0263386.
    PubMed     Abstract available


  30. SAKAMAKI A, Takamura M, Sakai N, Watanabe Y, et al
    Longitudinal increase in albumin-bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis.
    PLoS One. 2022;17:e0263464.
    PubMed     Abstract available


  31. LE BOUTILLIER C, Snowdon C, Patel V, McPhail M, et al
    Using a theory-informed approach to explore patient and staff perspectives on factors that influence clinical trial recruitment for patients with cirrhosis and small oesophageal varices.
    PLoS One. 2022;17:e0263288.
    PubMed     Abstract available


  32. SARMADI N, Poustchi H, Ali Yari F, Radmard AR, et al
    Anti-inflammatory function of apolipoprotein B-depleted plasma is impaired in non-alcoholic fatty liver disease.
    PLoS One. 2022;17:e0266227.
    PubMed     Abstract available


  33. KADDU-MULINDWA D, von Martial M, Thiel-Bodenstaff A, Lesan V, et al
    Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization.
    PLoS One. 2022;17:e0266069.
    PubMed     Abstract available


  34. KIM D, Kim JH, Ko DR, Min IK, et al
    Usefulness of contrast-enhanced multi-detector computed tomography in identifying upper gastrointestinal bleeding: A retrospective study of patients admitted to the emergency department.
    PLoS One. 2022;17:e0266622.
    PubMed     Abstract available


  35. ANENI EC, Saeed GJ, Bittencourt MS, Cainzos-Achirica M, et al
    Cardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals.
    PLoS One. 2022;17:e0266505.
    PubMed     Abstract available


  36. CAROL M, Perez-Guasch M, Sola E, Cervera M, et al
    Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life.
    PLoS One. 2022;17:e0265153.
    PubMed     Abstract available


  37. HAYASHI R, Kogiso T, Kikuchi N, Yamamoto K, et al
    Portopulmonary hypertension and the risk of high right ventricular systolic pressure in liver transplant candidates.
    PLoS One. 2022;17:e0267125.
    PubMed     Abstract available


  38. WORETA TA, Van Natta ML, Lazo M, Krishnan A, et al
    Validation of the accuracy of the FAST score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
    PLoS One. 2022;17:e0266859.
    PubMed     Abstract available


  39. SALMAN M, Kamel MA, El-Nabi SEH, Ismail AHA, et al
    The regulation of HBP1, SIRT1, and SREBP-1c genes and the related microRNAs in non-alcoholic fatty liver rats: The association with the folic acid anti-steatosis.
    PLoS One. 2022;17:e0265455.
    PubMed     Abstract available


  40. GHOSH A, Sarmah P, Patel H, Mukerjee N, et al
    Nonlinear molecular dynamics of quercetin in Gynocardia odorata and Diospyros malabarica fruits: Its mechanistic role in hepatoprotection.
    PLoS One. 2022;17:e0263917.
    PubMed     Abstract available


  41. NAKAZAWA M, Imai Y, Sugawara K, Uchida Y, et al
    Long-term outcomes of patients with cirrhosis presenting with bleeding gastric varices.
    PLoS One. 2022;17:e0264359.
    PubMed     Abstract available


  42. FU J, Gao Y, Shi L
    Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0267647.
    PubMed     Abstract available


  43. ISHII M, Itano O, Morinaga J, Shirakawa H, et al
    Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
    PLoS One. 2022;17:e0266707.
    PubMed     Abstract available


  44. GAIRING SJ, Galle PR, Schattenberg JM, Kostev K, et al
    Portal vein thrombosis is associated with an increased risk of bone fractures.
    PLoS One. 2022;17:e0267535.
    PubMed     Abstract available


  45. NGUYEN TB, Do DN, Nguyen TTP, Nguyen TL, et al
    Immune-related biomarkers shared by inflammatory bowel disease and liver cancer.
    PLoS One. 2022;17:e0267358.
    PubMed     Abstract available


  46. CHEN PC, Lee YC, Su YC, Lee CH, et al
    Does hepatectomy improve outcomes of breast cancer with liver metastasis? A nationwide analysis of real-world data in Taiwan.
    PLoS One. 2022;17:e0266960.
    PubMed     Abstract available


  47. BAEK M, Chai JC, Choi HI, Yoo E, et al
    Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells.
    PLoS One. 2022;17:e0266966.
    PubMed     Abstract available


  48. GOLD LC, Macpherson I, Nobes JH, Dow E, et al
    Thrombocytosis and abnormal liver enzymes: A trigger for investigation of underlying malignancy.
    PLoS One. 2022;17:e0267124.
    PubMed     Abstract available


  49. HU S, Zhang J, Guo G, Zhang L, et al
    Comprehensive analysis of GSEC/miR-101-3p/SNX16/PAPOLG axis in hepatocellular carcinoma.
    PLoS One. 2022;17:e0267117.
    PubMed     Abstract available


  50. MEZO M, Gonzalez-Warleta M, Castro-Hermida JA, Martinez-Sernandez V, et al
    Field evaluation of the enhanced MM3-COPRO ELISA test for the diagnosis of Fasciola hepatica infection in sheep.
    PLoS One. 2022;17:e0265569.
    PubMed     Abstract available


  51. HAMADA S, Takata T, Yamada K, Yamamoto M, et al
    Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model.
    PLoS One. 2022;17:e0265461.
    PubMed     Abstract available


  52. PENG CH, Ker YB, Li HH, Tsou SH, et al
    Abelmoschus esculentus subfractions ameliorate hepatic lipogenesis and lipid uptake via regulating dipeptidyl peptidase-4-With improving insulin resistance.
    PLoS One. 2022;17:e0265444.
    PubMed     Abstract available


  53. KANEKO S, Kurosaki M, Tsuchiya K, Yasui Y, et al
    Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.
    PLoS One. 2022;17:e0265235.
    PubMed     Abstract available


  54. GRASS JK, Kusters N, Kemper M, Tintrup J, et al
    Risk stratification of cirrhotic patients undergoing esophagectomy for esophageal cancer: A single-centre experience.
    PLoS One. 2022;17:e0265093.
    PubMed     Abstract available


  55. SAXENA R, Nassiri M, Yin XM, Morral N, et al
    Insights from a high-fat diet fed mouse model with a humanized liver.
    PLoS One. 2022;17:e0268260.
    PubMed     Abstract available


  56. HICKMAN TL, Choi E, Whiteman KR, Muralidharan S, et al
    BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
    PLoS One. 2022;17:e0266980.
    PubMed     Abstract available


  57. OH MK, Joo H, Kim IS
    Prohaptoglobin inhibits the transforming growth factor-beta-induced epithelial-to-mesenchymal transition in vitro by increasing Smad1/5 activation and suppressing the Smad2/3 signaling pathway in SK-Hep1 liver cancer cells.
    PLoS One. 2022;17:e0266409.
    PubMed     Abstract available


  58. ORR CE, Wang PL, Chen L, Wang T, et al
    Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma.
    PLoS One. 2022;17:e0267474.
    PubMed     Abstract available


  59. MUCKE VT, Peiffer KH, Kessel J, Schwarzkopf KM, et al
    Impact of colonization with multidrug-resistant organisms on antibiotic prophylaxis in patients with cirrhosis and variceal bleeding.
    PLoS One. 2022;17:e0268638.
    PubMed     Abstract available


  60. ZHANG XF, Lai L, Zhou H, Mo YJ, et al
    Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: A meta-analysis.
    PLoS One. 2022;17:e0268779.
    PubMed     Abstract available


  61. BESSHO R, Kashiwagi K, Ikura A, Yamataka K, et al
    A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
    PLoS One. 2022;17:e0269265.
    PubMed     Abstract available


  62. WANG L, Ding Y, Zhang C, Chen R, et al
    Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients.
    PLoS One. 2022;17:e0269249.
    PubMed     Abstract available


  63. THEVENOT T, Vendeville S, Weil D, Akkouche L, et al
    Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study.
    PLoS One. 2022;17:e0266965.
    PubMed     Abstract available


  64. LAUN FB, Fuhres T, Seuss H, Muller A, et al
    Flow-compensated diffusion encoding in MRI for improved liver metastasis detection.
    PLoS One. 2022;17:e0268843.
    PubMed     Abstract available


  65. RIDJAB DA, Ivan I, Budiman F, Tenggara R, et al
    Evaluation of subclinical ventricular systolic dysfunction assessed using global longitudinal strain in liver cirrhosis: A systematic review, meta-analysis, and meta-regression.
    PLoS One. 2022;17:e0269691.
    PubMed     Abstract available


  66. EFREMOV Y, Ermolaeva A, Vladimirov G, Gordleeva S, et al
    A mathematical model of in vitro hepatocellular cholesterol and lipoprotein metabolism for hyperlipidemia therapy.
    PLoS One. 2022;17:e0264903.
    PubMed     Abstract available


  67. LYNCH EC, Liu Z, Liu L, Wang X, et al
    Disrupting Osr1 expression promoted hepatic steatosis and inflammation induced by high-fat diet in the mouse model.
    PLoS One. 2022;17:e0268344.
    PubMed     Abstract available


  68. PARK J, Kwon HJ, Sohn W, Cho JY, et al
    Risk of liver fibrosis in patients with prediabetes and diabetes mellitus.
    PLoS One. 2022;17:e0269070.
    PubMed     Abstract available


  69. KOGISO T, Sagawa T, Taniai M, Shimada E, et al
    Risk factors for Fontan-associated hepatocellular carcinoma.
    PLoS One. 2022;17:e0270230.
    PubMed     Abstract available


    January 2021
  70. SPOGIS J, Hagen F, Thaiss WM, Hoffmann T, et al
    Sonographic findings in coronavirus disease-19 associated liver damage.
    PLoS One. 2021;16:e0244781.
    PubMed     Abstract available


  71. OHIRA S, Kanayama N, Wada K, Ikawa T, et al
    Improvement of image quality and assessment of respiratory motion for hepatocellular carcinoma with portal vein tumor thrombosis using contrast-enhanced four-dimensional dual-energy computed tomography.
    PLoS One. 2021;16:e0244079.
    PubMed     Abstract available


  72. ZHAO N, Tan H, Wang L, Han L, et al
    Palmitate induces fat accumulation via repressing FoxO1-mediated ATGL-dependent lipolysis in HepG2 hepatocytes.
    PLoS One. 2021;16:e0243938.
    PubMed     Abstract available


  73. SETO WK, Mandell MS
    Chronic liver disease: Global perspectives and future challenges to delivering quality health care.
    PLoS One. 2021;16:e0243607.
    PubMed    


  74. YEN YH, Cheng YF, Wang JH, Lin CC, et al
    Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West.
    PLoS One. 2021;16:e0244939.
    PubMed     Abstract available


  75. LI X, Zhong X, Wang Y, Zeng X, et al
    Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0250602.
    PubMed     Abstract available


  76. FERSTL PG, Filmann N, Heilgenthal EM, Schnitzbauer AA, et al
    Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates.
    PLoS One. 2021;16:e0245091.
    PubMed     Abstract available


  77. DA FONSECA RD, Santos PR, Monteiro MS, Fernandes LA, et al
    Parametric evaluation of impedance curve in radiofrequency ablation: A quantitative description of the asymmetry and dynamic variation of impedance in bovine ex vivo model.
    PLoS One. 2021;16:e0245145.
    PubMed     Abstract available


  78. FRANKOVA S, Lunova M, Gottfriedova H, Senkerikova R, et al
    Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis.
    PLoS One. 2021;16:e0244934.
    PubMed     Abstract available


  79. WANG F, Numata K, Takeda A, Ogushi K, et al
    Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma.
    PLoS One. 2021;16:e0245076.
    PubMed     Abstract available


  80. CARTER JK, Bhattacharya D, Borgerding JN, Fiel MI, et al
    Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.
    PLoS One. 2021;16:e0244763.
    PubMed     Abstract available


  81. JOBIRA B, Frank DN, Silveira LJ, Pyle L, et al
    Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome.
    PLoS One. 2021;16:e0245219.
    PubMed     Abstract available


  82. FATTAHI N, Rezaei N, Asadi-Lari M, Yousefi M, et al
    Hepatocellular carcinoma incidence at national and provincial levels in Iran from 2000 to 2016: A meta-regression analysis.
    PLoS One. 2021;16:e0245468.
    PubMed     Abstract available


  83. VAN AMERONGEN MJ, Vos AM, van der Woude W, Nagtegaal ID, et al
    Does perfusion computed tomography correlate to pathology in colorectal liver metastases?
    PLoS One. 2021;16:e0245764.
    PubMed     Abstract available


  84. CHENG K, Liu W, You J, Shah S, et al
    Safety of laparoscopic pancreaticoduodenectomy in patients with liver cirrhosis using propensity score matching.
    PLoS One. 2021;16:e0246364.
    PubMed     Abstract available


  85. CHO Y, Lee S, Park SJ
    Effectiveness of intraprocedural dual-phase cone-beam computed tomography in detecting hepatocellular carcinoma and improving treatment outcomes following conventional transarterial chemoembolization.
    PLoS One. 2021;16:e0245911.
    PubMed     Abstract available


  86. LIN X, You F, Liu H, Fang Y, et al
    Site-specific risk of colorectal neoplasms in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0245921.
    PubMed     Abstract available


  87. CHEN BW, Chiu GW, He YC, Huang CY, et al
    Extracellular and intracellular intermittent magnetic-fluid hyperthermia treatment of SK-Hep1 hepatocellular carcinoma cells based on magnetic nanoparticles coated with polystyrene sulfonic acid.
    PLoS One. 2021;16:e0245286.
    PubMed     Abstract available


  88. NIRIELLA MA, Ediriweera DS, Kasturiratne A, De Silva ST, et al
    Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.
    PLoS One. 2021;16:e0245762.
    PubMed     Abstract available


  89. MENDOZA N, Rivas E, Rodriguez-Roisin R, Garcia T, et al
    Liver epigenome changes in patients with hepatopulmonary syndrome: A pilot study.
    PLoS One. 2021;16:e0245046.
    PubMed     Abstract available


  90. VOGL TJ, Riegelbauer LJ, Oppermann E, Kostantin M, et al
    Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments in patients with hepatocellular carcinoma.
    PLoS One. 2021;16:e0246527.
    PubMed     Abstract available


  91. SEO N, Park MS, Choi JY, Yeom JS, et al
    A prospective study on the use of ultralow-dose computed tomography with iterative reconstruction for the follow-up of patients liver and renal abscess.
    PLoS One. 2021;16:e0246532.
    PubMed     Abstract available


  92. ASSIS JB, Cogliati B, Esteves E, Capurro ML, et al
    Aedes aegypti mosquito saliva ameliorates acetaminophen-induced liver injury in mice.
    PLoS One. 2021;16:e0245788.
    PubMed     Abstract available


  93. TANAKA T, Hirooka M, Koizumi Y, Watanabe T, et al
    Development of a method for measuring spleen stiffness by transient elastography using a new device and ultrasound-fusion method.
    PLoS One. 2021;16:e0246315.
    PubMed     Abstract available


  94. KIM YA, Kang D, Moon H, Sinn D, et al
    Survival in untreated hepatocellular carcinoma: A national cohort study.
    PLoS One. 2021;16:e0246143.
    PubMed     Abstract available


  95. FUKUYAMA K, Asagiri M, Sugimoto M, Tsushima H, et al
    Gene expression profiles of liver cancer cell lines reveal two hepatocyte-like and fibroblast-like clusters.
    PLoS One. 2021;16:e0245939.
    PubMed     Abstract available


  96. STAHLSCHMIDT FL, Tafarel JR, Menini-Stahlschmidt CM, Baena CP, et al
    Hepatorenal index for grading liver steatosis with concomitant fibrosis.
    PLoS One. 2021;16:e0246837.
    PubMed     Abstract available


  97. TOMITA K, Chiba N, Ochiai S, Gunji T, et al
    Prognostic value of future liver remnant LU15 index of 99mTc-galactosyl serum albumin scintigraphy for predicting posthepatectomy liver failure.
    PLoS One. 2021;16:e0247675.
    PubMed     Abstract available


  98. KOVAC JD, Dakovic M, Jankovic A, Mitrovic M, et al
    The role of quantitative diffusion-weighted imaging in characterization of hypovascular liver lesions: A prospective comparison of intravoxel incoherent motion derived parameters and apparent diffusion coefficient.
    PLoS One. 2021;16:e0247301.
    PubMed     Abstract available


  99. KIMANYA ME, Routledge MN, Mpolya E, Ezekiel CN, et al
    Estimating the risk of aflatoxin-induced liver cancer in Tanzania based on biomarker data.
    PLoS One. 2021;16:e0247281.
    PubMed     Abstract available


  100. CHO WR, Wang CC, Tsai MY, Chou CK, et al
    Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients.
    PLoS One. 2021;16:e0247231.
    PubMed     Abstract available


  101. POMEJ K, Scheiner B, Hartl L, Balcar L, et al
    COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital.
    PLoS One. 2021;16:e0256544.
    PubMed     Abstract available


  102. SHIGESAWA T, Suda G, Kimura M, Maehara O, et al
    Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
    PLoS One. 2021;16:e0247728.
    PubMed     Abstract available


  103. NAKADE Y, Kitano R, Sakamoto K, Kimoto S, et al
    Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats.
    PLoS One. 2021;16:e0247303.
    PubMed     Abstract available


  104. TAKASE T, Toyoda T, Kobayashi N, Inoue T, et al
    Dietary iso-alpha-acids prevent acetaldehyde-induced liver injury through Nrf2-mediated gene expression.
    PLoS One. 2021;16:e0246327.
    PubMed     Abstract available


  105. HODEIFY R, Chakkour M, Rida R, Kreydiyyeh S, et al
    PGE2 upregulates the Na+/K+ ATPase in HepG2 cells via EP4 receptors and intracellular calcium.
    PLoS One. 2021;16:e0245400.
    PubMed     Abstract available


  106. KURODA H, Fujiwara Y, Abe T, Nagasawa T, et al
    Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis.
    PLoS One. 2021;16:e0249493.
    PubMed     Abstract available


  107. D'AMBROSIO R, Campi I, Maggioni M, Perbellini R, et al
    The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD).
    PLoS One. 2021;16:e0249614.
    PubMed     Abstract available


  108. BUSQUETS-CORTES C, Bennasar-Veny M, Lopez-Gonzalez AA, Fresneda S, et al
    Utility of Fatty Liver Index to predict reversion to normoglycemia in people with prediabetes.
    PLoS One. 2021;16:e0249221.
    PubMed     Abstract available


  109. BEYER C, Hutton C, Andersson A, Imajo K, et al
    Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort.
    PLoS One. 2021;16:e0249491.
    PubMed     Abstract available


  110. KAPS L, Ahlbrand CJ, Gadban R, Nagel M, et al
    Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care.
    PLoS One. 2021;16:e0249342.
    PubMed     Abstract available


  111. ARIYA M, Koohpayeh F, Ghaemi A, Osati S, et al
    Assessment of the association between body composition and risk of non-alcoholic fatty liver.
    PLoS One. 2021;16:e0249223.
    PubMed     Abstract available


  112. CHEN Y, Xu Z, Zeng Y, Liu J, et al
    Altered metabolism by autophagy defection affect liver regeneration.
    PLoS One. 2021;16:e0250578.
    PubMed     Abstract available


  113. TAHA MM, Aneis YM, Mohamady HM, S A A, et al
    Effect of focused ultrasound cavitation augmented with aerobic exercise on abdominal and intrahepatic fat in patients with non-alcoholic fatty liver disease: A randomized controlled trial.
    PLoS One. 2021;16:e0250337.
    PubMed     Abstract available


  114. KOUTOUKIDIS DA, Morris E, Henry JA, Shammoon Y, et al
    What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0250385.
    PubMed     Abstract available


  115. NAYAN SI, Chowdhury FI, Akter N, Rahman MM, et al
    Leaf powder supplementation of Senna alexandrina ameliorates oxidative stress, inflammation, and hepatic steatosis in high-fat diet-fed obese rats.
    PLoS One. 2021;16:e0250261.
    PubMed     Abstract available


  116. WANG R, Hu X, Liu X, Bai L, et al
    Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
    PLoS One. 2021;16:e0249881.
    PubMed     Abstract available


  117. PARK JW, Jeong JM, Cho KS, Cho SY, et al
    MiR-30a and miR-200c differentiate cholangiocarcinomas from gastrointestinal cancer liver metastases.
    PLoS One. 2021;16:e0250083.
    PubMed     Abstract available


  118. HOSHI H, Chu PS, Yoshida A, Taniki N, et al
    Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis.
    PLoS One. 2021;16:e0250062.
    PubMed     Abstract available


  119. KIM JY, Park YM, Lee GN, Song HC, et al
    Association between toothbrushing and non-alcoholic fatty liver disease.
    PLoS One. 2021;16:e0243686.
    PubMed     Abstract available


  120. MAHRINGER-KUNZ A, Steinle V, Kloeckner R, Schotten S, et al
    The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.
    PLoS One. 2021;16:e0249426.
    PubMed     Abstract available


  121. NG YZ, Lai LL, Wong SW, Mohamad SY, et al
    Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease.
    PLoS One. 2021;16:e0250300.
    PubMed     Abstract available


  122. EDER M, Omic H, Gorges J, Badt F, et al
    Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease.
    PLoS One. 2021;16:e0249785.
    PubMed     Abstract available


  123. SAEKI C, Saito M, Kanai T, Nakano M, et al
    Plasma pentosidine levels are associated with prevalent fractures in patients with chronic liver disease.
    PLoS One. 2021;16:e0249728.
    PubMed     Abstract available


  124. SENGUPTA M, Abuirqeba S, Kameric A, Cecile-Valfort A, et al
    A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis.
    PLoS One. 2021;16:e0249316.
    PubMed     Abstract available


  125. KEHL T, Biermann D, Briem-Richter A, Schoen G, et al
    Impact of hepatopathy in pediatric patients after surgery for complex congenital heart disease.
    PLoS One. 2021;16:e0248776.
    PubMed     Abstract available


  126. LIN SY, Chen CM, Huang BS, Lai YC, et al
    A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness.
    PLoS One. 2021;16:e0249003.
    PubMed     Abstract available


  127. MISHIMA K, Itano O, Matsuda S, Suzuki S, et al
    Development of human hepatocellular carcinoma in X-linked severe combined immunodeficient pigs: An orthotopic xenograft model.
    PLoS One. 2021;16:e0248352.
    PubMed     Abstract available


  128. HUANG CY, Chang YJ, Wei PL, Hung CS, et al
    Methyl gallate, gallic acid-derived compound, inhibit cell proliferation through increasing ROS production and apoptosis in hepatocellular carcinoma cells.
    PLoS One. 2021;16:e0248521.
    PubMed     Abstract available


  129. LOOSEN SH, Castoldi M, Jordens MS, Roy S, et al
    Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC.
    PLoS One. 2021;16:e0247917.
    PubMed     Abstract available


  130. DE MUNCK TJI, Boesch M, Verhaegh P, Masclee AAM, et al
    Is there a role for neuregulin 4 in human nonalcoholic fatty liver disease?
    PLoS One. 2021;16:e0251822.
    PubMed     Abstract available


  131. YEN YH, Cheng YF, Wang JH, Lin CC, et al
    Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias.
    PLoS One. 2021;16:e0249194.
    PubMed     Abstract available


  132. LEMIEUX S, Buies A, F Turgeon A, Hallet J, et al
    Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0247958.
    PubMed     Abstract available


  133. MORAN MW, Ramirez EP, Zook JD, Saarinen AM, et al
    Biophysical characterization and a roadmap towards the NMR solution structure of G0S2, a key enzyme in non-alcoholic fatty liver disease.
    PLoS One. 2021;16:e0249164.
    PubMed     Abstract available


  134. JUSTINO AB, Florentino RM, Franca A, Filho ACML, et al
    Alkaloid and acetogenin-rich fraction from Annona crassiflora fruit peel inhibits proliferation and migration of human liver cancer HepG2 cells.
    PLoS One. 2021;16:e0250394.
    PubMed     Abstract available


  135. ZHANG X, Heredia NI, Balakrishnan M, Thrift AP, et al
    Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
    PLoS One. 2021;16:e0252164.
    PubMed     Abstract available


  136. BERNARDO S, Crespo R, Saraiva S, Barata R, et al
    Outcomes of excessive alcohol drinkers without baseline evidence of chronic liver disease after 15 years follow-up: Heavy burden of cancer and liver disease mortality.
    PLoS One. 2021;16:e0252218.
    PubMed     Abstract available


  137. BROERING D, Shawkat M, Albenmousa A, Abaalkhail F, et al
    Validating controlled attenuation parameter in the assessment of hepatic steatosis in living liver donors.
    PLoS One. 2021;16:e0251487.
    PubMed     Abstract available


  138. PEREIRA R, Buglevski M, Perdigoto R, Marcelino P, et al
    Intra-abdominal hypertension and abdominal compartment syndrome in the critically ill liver cirrhotic patient-prevalence and clinical outcomes. A multicentric retrospective cohort study in intensive care.
    PLoS One. 2021;16:e0251498.
    PubMed     Abstract available


  139. YOUNG P, Tarce P, Adhikary S, Connolly J, et al
    Evaluation of high-resolution melt curve analysis for rapid differentiation of Campylobacter hepaticus from other species in birds.
    PLoS One. 2021;16:e0251328.
    PubMed     Abstract available


  140. HE Y, Xu R, Peng L, Hu X, et al
    Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis.
    PLoS One. 2021;16:e0254829.
    PubMed     Abstract available


  141. DAYTON KA, Bril F, Barb D, Lai J, et al
    Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.
    PLoS One. 2021;16:e0251449.
    PubMed     Abstract available


  142. KAPS L, Hildebrand K, Nagel M, Michel M, et al
    Risk factors for poorer health literacy in patients with liver cirrhosis.
    PLoS One. 2021;16:e0255349.
    PubMed     Abstract available


  143. LEE Y, Mun E, Park S, Lee W, et al
    Long working hours are associated with a higher risk of non-alcoholic fatty liver disease: A large population-based Korean cohort study.
    PLoS One. 2021;16:e0255118.
    PubMed     Abstract available


  144. HALFON P, Ansaldi C, Penaranda G, Chiche L, et al
    Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results.
    PLoS One. 2021;16:e0254939.
    PubMed     Abstract available


  145. KHORPRASERT C, Thonglert K, Alisanant P, Amornwichet N, et al
    Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: Feasibility and clinical outcomes.
    PLoS One. 2021;16:e0257556.
    PubMed     Abstract available


  146. WEN X, Wang S, Taveira TH, Akhlaghi F, et al
    Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH).
    PLoS One. 2021;16:e0251665.
    PubMed     Abstract available


  147. COUBARD OA, Ober KM, Gaumet M, Urbanski M, et al
    Standardization of the psychometric hepatic encephalopathy score in a French population.
    PLoS One. 2021;16:e0257136.
    PubMed     Abstract available


  148. CHANG Y, Han JA, Kang SM, Jeong SW, et al
    Clinical impact of serum exosomal microRNA in liver fibrosis.
    PLoS One. 2021;16:e0255672.
    PubMed     Abstract available


  149. GAO L, Morine Y, Yamada S, Saito Y, et al
    Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
    PLoS One. 2021;16:e0256755.
    PubMed     Abstract available


  150. WAQAR W, Asghar S, Manzoor S
    Platelets' RNA as biomarker trove for differentiation of early-stage hepatocellular carcinoma from underlying cirrhotic nodules.
    PLoS One. 2021;16:e0256739.
    PubMed     Abstract available


  151. STRUCK MF, Kliem P, Ebel S, Bauer A, et al
    Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery.
    PLoS One. 2021;16:e0254817.
    PubMed     Abstract available


  152. SUKAHRI S, Mohamed Shah FZ, Ismail AI, Koshy M, et al
    Significantly higher atherosclerosis risks in patients with obstructive sleep apnea and non-alcoholic fatty liver disease.
    PLoS One. 2021;16:e0253298.
    PubMed     Abstract available


  153. SHI X, Li J, Min B, Yang R, et al
    Application of ultrasound elastography for monitoring the effects of TbetaR1 shRNA therapy on hepatic fibrosis in a rat model.
    PLoS One. 2021;16:e0253150.
    PubMed     Abstract available


  154. SHIMIZU Y, Sasaki T, Takeshita JI, Watanabe M, et al
    Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs.
    PLoS One. 2021;16:e0253855.
    PubMed     Abstract available


  155. LEE JW, Hwang JS, Chung WJ, Lee HJ, et al
    Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites.
    PLoS One. 2021;16:e0253886.
    PubMed     Abstract available


  156. REIMER RP, Hokamp NG, Niehoff J, Zopfs D, et al
    Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma.
    PLoS One. 2021;16:e0252678.
    PubMed     Abstract available


  157. JO HH, Min C, Kyoung DS, Park MA, et al
    Adverse outcomes after surgeries in patients with liver cirrhosis among Korean population: A population-based study.
    PLoS One. 2021;16:e0253165.
    PubMed     Abstract available


  158. TIYARATTANACHAI T, Apiparakoon T, Marukatat S, Sukcharoen S, et al
    Development and validation of artificial intelligence to detect and diagnose liver lesions from ultrasound images.
    PLoS One. 2021;16:e0252882.
    PubMed     Abstract available


  159. ROUNIS K, Makrakis D, Papadaki C, Monastirioti A, et al
    Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    PLoS One. 2021;16:e0252537.
    PubMed     Abstract available


  160. ZHOU J, Zhu Y, Ma S, Li Y, et al
    Bioinformatics analysis identifies DYNC1I1 as prognosis marker in male patients with liver hepatocellular carcinoma.
    PLoS One. 2021;16:e0258797.
    PubMed     Abstract available


  161. XIE Y, Liu C, Zhang Y, Li A, et al
    PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair.
    PLoS One. 2021;16:e0258817.
    PubMed     Abstract available


  162. HSU PK, Wu LS, Su WW, Su PY, et al
    Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis.
    PLoS One. 2021;16:e0254892.
    PubMed     Abstract available


  163. ISOURA Y, Yamamoto A, Cho Y, Ehara E, et al
    Platelet count and abdominal dynamic CT are useful in predicting and screening for gastroesophageal varices after Fontan surgery.
    PLoS One. 2021;16:e0257441.
    PubMed     Abstract available


  164. WANG Y, Xiao X, Wang X, Guo F, et al
    Identification of differentially expressed long noncoding RNAs and pathways in liver tissues from rats with hepatic fibrosis.
    PLoS One. 2021;16:e0258194.
    PubMed     Abstract available


  165. KHAMIS ZI, Pang X, Cui Z, Sang QA, et al
    Cytochrome P450-2D6: A novel biomarker in liver cancer health disparity.
    PLoS One. 2021;16:e0257072.
    PubMed     Abstract available


  166. CHUAYPEN N, Limothai U, Kunadirek P, Kaewsapsak P, et al
    Identification and validation of circulating miRNAs as potential new biomarkers for severe liver disease in patients with leptospirosis.
    PLoS One. 2021;16:e0257805.
    PubMed     Abstract available


  167. PARK JH, Chung YE, Seo N, Choi JY, et al
    Hepatobiliary phase signal intensity: A potential method of diagnosing HCC with atypical imaging features among LR-M observations.
    PLoS One. 2021;16:e0257308.
    PubMed     Abstract available


  168. LI M, Hu M, Yue Z, Zhang Y, et al
    The interactive effects of non-alcoholic fatty liver disease and hemoglobin concentration in the first trimester on the development of gestational diabetes mellitus.
    PLoS One. 2021;16:e0257391.
    PubMed     Abstract available


  169. BHATT SP, Guleria R
    Association of IRS1 (Gly972Arg) and IRS2 (Gly1057Asp) genes polymorphisms with OSA and NAFLD in Asian Indians.
    PLoS One. 2021;16:e0245408.
    PubMed     Abstract available


  170. HUNOLD P, Berg T, Seehofer D, Sucher R, et al
    Experiences from six years of quality assured Model of End Stage Liver Disease (MELD) diagnostics.
    PLoS One. 2021;16:e0254219.
    PubMed     Abstract available


  171. YANG CJ, Wang CK, Fang YD, Wang JY, et al
    Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets.
    PLoS One. 2021;16:e0255605.
    PubMed     Abstract available


  172. MINICOZZI MR, Axlid EG, von Hippel FA, Espinoza J, et al
    Perchlorate exposure does not induce obesity or non-alcoholic fatty liver disease in zebrafish.
    PLoS One. 2021;16:e0254500.
    PubMed     Abstract available


  173. WU PS, Hsieh YC, Lee KC, Huang YH, et al
    Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients.
    PLoS One. 2021;16:e0258589.
    PubMed     Abstract available


  174. KOO DJ, Lee MY, Jung I, Moon SJ, et al
    Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study.
    PLoS One. 2021;16:e0255535.
    PubMed     Abstract available


  175. TRAN BV, Ujita K, Taketomi-Takahashi A, Hirasawa H, et al
    Reliability of ultrasound hepatorenal index and magnetic resonance imaging proton density fat fraction techniques in the diagnosis of hepatic steatosis, with magnetic resonance spectroscopy as the reference standard.
    PLoS One. 2021;16:e0255768.
    PubMed     Abstract available


  176. KITAZAWA A, Maeda S, Fukuda Y
    Fatty liver index as a predictive marker for the development of diabetes: A retrospective cohort study using Japanese health check-up data.
    PLoS One. 2021;16:e0257352.
    PubMed     Abstract available


  177. STARITZBICHLER R, Hunold P, Estrela-Lopis I, Hildebrand PW, et al
    Raman spectroscopy on blood serum samples of patients with end-stage liver disease.
    PLoS One. 2021;16:e0256045.
    PubMed     Abstract available


  178. FREISE C, Lee H, Chronowski C, Chan D, et al
    Alpha-single chains of collagen type VI inhibit the fibrogenic effects of triple helical collagen VI in hepatic stellate cells.
    PLoS One. 2021;16:e0254557.
    PubMed     Abstract available


  179. GUO A, Mazumder NR, Ladner DP, Foraker RE, et al
    Predicting mortality among patients with liver cirrhosis in electronic health records with machine learning.
    PLoS One. 2021;16:e0256428.
    PubMed     Abstract available


  180. UHLIG M, Hein M, Habigt MA, Tolba RH, et al
    Acute myocardial injury secondary to severe acute liver failure: A retrospective analysis supported by animal data.
    PLoS One. 2021;16:e0256790.
    PubMed     Abstract available


  181. CHERCHI V, Vetrugno L, Terrosu G, Zanini V, et al
    Association between the donor to recipient ICG-PDR variation rate and the functional recovery of the graft after orthotopic liver transplantation: A case series.
    PLoS One. 2021;16:e0256786.
    PubMed     Abstract available


  182. QUECK A, Uschner FE, Ferstl PG, Schulz M, et al
    Role of circulating angiogenin levels in portal hypertension and TIPS.
    PLoS One. 2021;16:e0256473.
    PubMed     Abstract available


  183. GARCIA-CHAVEZ JN, Vasquez-Garzon VR, Lopez MG, Villa-Trevino S, et al
    Integration of chronological omics data reveals mitochondrial regulatory mechanisms during the development of hepatocellular carcinoma.
    PLoS One. 2021;16:e0256016.
    PubMed     Abstract available


  184. MARINI TJ, Oppenheimer DC, Baran TM, Rubens DJ, et al
    Testing telediagnostic right upper quadrant abdominal ultrasound in Peru: A new horizon in expanding access to imaging in rural and underserved areas.
    PLoS One. 2021;16:e0255919.
    PubMed     Abstract available


  185. GIM JA, Bang SM, Lee YS, Lee Y, et al
    Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression.
    PLoS One. 2021;16:e0255822.
    PubMed     Abstract available


  186. BI J, Guo Y, Li Q, Liu L, et al
    Role of long intergenic non-protein coding RNA 01857 in hepatocellular carcinoma malignancy via the regulation of the microRNA-197-3p/anterior GRadient 2 axis.
    PLoS One. 2021;16:e0258312.
    PubMed     Abstract available


  187. ALBAKHEET SS, Lee MJ, Yoon H, Shin HJ, et al
    Psoas muscle area and paraspinal muscle fat in children and young adults with or without obesity and fatty liver.
    PLoS One. 2021;16:e0259948.
    PubMed     Abstract available


  188. GORJI-BAHRI G, Moradtabrizi N, Hashemi A
    Uncovering the stability status of the reputed reference genes in breast and hepatic cancer cell lines.
    PLoS One. 2021;16:e0259669.
    PubMed     Abstract available


  189. BULUT G, Guner Oytun M, Almuradova E, Harman M, et al
    Contribution of "complete response to treatment" to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis.
    PLoS One. 2021;16:e0259622.
    PubMed     Abstract available


  190. SCHOLER D, Castoldi M, Jordens MS, Schulze-Hagen M, et al
    Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series.
    PLoS One. 2021;16:e0255983.
    PubMed     Abstract available


  191. MAREK G, Collinsworth A, Liu C, Brantly M, et al
    Quantitative measurement of the histological features of alpha-1 antitrypsin deficiency-associated liver disease in biopsy specimens.
    PLoS One. 2021;16:e0256117.
    PubMed     Abstract available


  192. LEE SW, Kim SM, Hur W, Kang BY, et al
    Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway.
    PLoS One. 2021;16:e0261067.
    PubMed     Abstract available


  193. RADY B, Nishio T, Dhar D, Liu X, et al
    PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells.
    PLoS One. 2021;16:e0260721.
    PubMed     Abstract available


  194. SVECIC A, Mansour R, Tang A, Kadoury S, et al
    Prediction of post transarterial chemoembolization MR images of hepatocellular carcinoma using spatio-temporal graph convolutional networks.
    PLoS One. 2021;16:e0259692.
    PubMed     Abstract available


  195. KUANG L, Zhou W, Jiang Y
    Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis.
    PLoS One. 2021;16:e0260479.
    PubMed     Abstract available


  196. HAN JW, Sung PS, Jang JW, Choi JY, et al
    Whole blood viscosity is associated with extrahepatic metastases and survival in patients with hepatocellular carcinoma.
    PLoS One. 2021;16:e0260311.
    PubMed     Abstract available


  197. ESKRIDGE W, Vierling JM, Gosbee W, Wan GA, et al
    Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE).
    PLoS One. 2021;16:e0260320.
    PubMed     Abstract available


  198. MOSTAFA RE, Shaffie NM, Allam RM
    Panax Ginseng alleviates thioacetamide-induced liver injury in ovariectomized rats: Crosstalk between inflammation and oxidative stress.
    PLoS One. 2021;16:e0260507.
    PubMed     Abstract available


  199. NAH EH, Cho S, Park H, Noh D, et al
    Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study.
    PLoS One. 2021;16:e0260477.
    PubMed     Abstract available


  200. GOYALE A, Jain A, Smith C, Papatheodoridi M, et al
    Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study.
    PLoS One. 2021;16:e0260313.
    PubMed     Abstract available


  201. JANG DK, Ahn DW, Lee KL, Kim BG, et al
    Impacts of body composition parameters and liver cirrhosis on the severity of alcoholic acute pancreatitis.
    PLoS One. 2021;16:e0260309.
    PubMed     Abstract available


  202. TAKASU C, Yamashita S, Morine Y, Yoshikawa K, et al
    The role of the immunoescape in colorectal cancer liver metastasis.
    PLoS One. 2021;16:e0259940.
    PubMed     Abstract available


  203. NAKAGOMI R, Tateishi R, Mikami S, Wake T, et al
    Infectious complications related to radiofrequency ablation of liver tumors: The role of antibiotics.
    PLoS One. 2021;16:e0259641.
    PubMed     Abstract available


  204. ABDEL-RAHMAN RF, Fayed HM, Asaad GF, Ogaly HA, et al
    The involvement of TGF-beta1 /FAK/alpha-SMA pathway in the antifibrotic impact of rice bran oil on thioacetamide-induced liver fibrosis in rats.
    PLoS One. 2021;16:e0260130.
    PubMed     Abstract available


  205. BARTON JC, Barton JC, Patel N, McLaren GD, et al
    Abdominal pain and cirrhosis at diagnosis of hemochromatosis: Analysis of 219 referred probands with HFE p.C282Y homozygosity and a literature review.
    PLoS One. 2021;16:e0261690.
    PubMed     Abstract available


  206. AGBALAJOBI OM, Gmelin T, Moon AM, Alexandre W, et al
    Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action.
    PLoS One. 2021;16:e0261377.
    PubMed     Abstract available


  207. HAN YM, Lee J, Choi JM, Kwak MS, et al
    The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors.
    PLoS One. 2021;16:e0260994.
    PubMed     Abstract available


  208. DERMAUW V, Muchai J, Al Kappany Y, Fajardo Castaneda AL, et al
    Human fascioliasis in Africa: A systematic review.
    PLoS One. 2021;16:e0261166.
    PubMed     Abstract available


  209. GROSS M, Spektor M, Jaffe A, Kucukkaya AS, et al
    Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging.
    PLoS One. 2021;16:e0260630.
    PubMed     Abstract available


  210. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
    The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
    PLoS One. 2021;16:e0251934.
    PubMed     Abstract available


  211. THOMAS JN, Roopkumar J, Patel T
    Machine learning analysis of volatolomic profiles in breath can identify non-invasive biomarkers of liver disease: A pilot study.
    PLoS One. 2021;16:e0260098.
    PubMed     Abstract available


  212. FRUNDT T, Kuballa L, Lutgehetman M, Norz D, et al
    Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic.
    PLoS One. 2021;16:e0258450.
    PubMed     Abstract available


    January 2020
  213. KLEIN WM, Sonnemans LJP, Franckenberg S, Fliss B, et al
    Pseudolesion in the right parafissural liver parenchyma on CT: The base is found in embryology and collagen content.
    PLoS One. 2020;15:e0221544.
    PubMed     Abstract available


  214. LEE JM, Park YM, Yun JS, Ahn YB, et al
    The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study.
    PLoS One. 2020;15:e0226351.
    PubMed     Abstract available


  215. JUN BG, Lee WC, Jang JY, Jeong SW, et al
    Relation of fibroblast growth factor receptor 2 expression to hepatocellular carcinoma recurrence after liver resection.
    PLoS One. 2020;15:e0227440.
    PubMed     Abstract available


  216. LIN Y, Li H, Jin C, Wang H, et al
    The diagnostic accuracy of liver fibrosis in non-viral liver diseases using acoustic radiation force impulse elastography: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0227358.
    PubMed     Abstract available


  217. RAHMAN MM, Zhang C, Swe KT, Rahman MS, et al
    Disease-specific out-of-pocket healthcare expenditure in urban Bangladesh: A Bayesian analysis.
    PLoS One. 2020;15:e0227565.
    PubMed     Abstract available


  218. DU S, Yang JZ, Chen J, Zhou WG, et al
    Comparisons of recurrence-free survival and overall survival between microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: A multiple centers retrospective cohort study with propensity score matching.
    PLoS One. 2020;15:e0227242.
    PubMed     Abstract available


  219. HAUBOLD J, Ludwig JM, Li Y, Buechter M, et al
    Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization.
    PLoS One. 2020;15:e0227972.
    PubMed     Abstract available


  220. MATSUMOTO M, Yashiro H, Ogino H, Aoyama K, et al
    Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
    PLoS One. 2020;15:e0228212.
    PubMed     Abstract available


  221. RAIGANI S, Karimian N, Huang V, Zhang AM, et al
    Metabolic and lipidomic profiling of steatotic human livers during ex situ normothermic machine perfusion guides resuscitation strategies.
    PLoS One. 2020;15:e0228011.
    PubMed     Abstract available


  222. TSUKUDA S, Ikeura T, Ito T, Nakamaru K, et al
    Clinical implications of elevated serum interleukin-6 in IgG4-related disease.
    PLoS One. 2020;15:e0227479.
    PubMed     Abstract available


  223. OKAMOTO K, Koda M, Okamoto T, Onoyama T, et al
    Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease.
    PLoS One. 2020;15:e0219412.
    PubMed     Abstract available


  224. ARTHUIS C, Diguisto C, Lorphelin H, Dochez V, et al
    Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study.
    PLoS One. 2020;15:e0228213.
    PubMed     Abstract available


  225. YANG B, Liang J, Qu Z, Yang F, et al
    Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.
    PLoS One. 2020;15:e0227475.
    PubMed     Abstract available


  226. LANZA E, Muglia R, Bolengo I, Poretti D, et al
    Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization.
    PLoS One. 2020;15:e0227711.
    PubMed     Abstract available


  227. SEO JY, Lee JE, Chung GE, Shin E, et al
    A genome-wide association study on liver enzymes in Korean population.
    PLoS One. 2020;15:e0229374.
    PubMed     Abstract available


  228. DIAZ-RIVERA A, Meza-Rios A, Chagoya de Sanchez V, Velasco-Loyden G, et al
    Hydrodynamics-based liver transfection achieves gene silencing of CB1 using short hairpin RNA plasmid in cirrhotic rats.
    PLoS One. 2020;15:e0228729.
    PubMed     Abstract available


  229. VAZQUEZ C, Gonzalez ML, Ferraris A, Bandi JC, et al
    Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.
    PLoS One. 2020;15:e0228486.
    PubMed     Abstract available


  230. DINIZ MFHS, Beleigoli AMR, Bensenor IM, Lotufo PA, et al
    Association between TSH levels within the reference range and adiposity markers at the baseline of the ELSA-Brasil study.
    PLoS One. 2020;15:e0228801.
    PubMed     Abstract available


  231. LIANG X, Shu W, Linyong Z, Jianshui L, et al
    Preoperative nutritional evaluation of patients with hepatic alveolar echinococcosis.
    PLoS One. 2020;15:e0229396.
    PubMed     Abstract available


  232. CHANG TS, Tsai YH, Lin YH, Chen CH, et al
    Limited effects of antibiotic prophylaxis in patients with Child-Pugh class A/B cirrhosis and upper gastrointestinal bleeding.
    PLoS One. 2020;15:e0229101.
    PubMed     Abstract available


  233. GIANNELLI G, Santoro A, Kelley RK, Gane E, et al
    Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-betaRI inhibitor galunisertib.
    PLoS One. 2020;15:e0222259.
    PubMed     Abstract available


  234. ZHANG J, Chen G, Zhang P, Zhang J, et al
    The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0228857.
    PubMed     Abstract available


  235. KELLER LM, Eighmy S, Li C, Winter L, et al
    Association of novel markers of liver disease with neonatal liver disease in premature baboons, Papio sp.
    PLoS One. 2020;15:e0228985.
    PubMed     Abstract available


  236. DING W, Tan Y, Qian Y, Xue W, et al
    First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials.
    PLoS One. 2020;15:e0229492.
    PubMed     Abstract available


  237. MOON AM, Jiang Y, Rogal SS, Becker J, et al
    In inpatients with cirrhosis opioid use is common and associated with length of stay and persistent use post-discharge.
    PLoS One. 2020;15:e0229497.
    PubMed     Abstract available


  238. LIN N, Li J, Ke Q, Xin F, et al
    Does the intermittent Pringle maneuver affect the recurrence following surgical resection for hepatocellular carcinoma? A systematic review.
    PLoS One. 2020;15:e0229870.
    PubMed     Abstract available


  239. CHOI J, Lee D, Shim JH, Kim KM, et al
    Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma.
    PLoS One. 2020;15:e0229696.
    PubMed     Abstract available


  240. WARD MD, King MA, Gabrial C, Kenefick RW, et al
    Biochemical recovery from exertional heat stroke follows a 16-day time course.
    PLoS One. 2020;15:e0229616.
    PubMed     Abstract available


  241. MITCHELL RA, Rathi S, Dahiya M, Zhu J, et al
    Public awareness of acetaminophen and risks of drug induced liver injury: Results of a large outpatient clinic survey.
    PLoS One. 2020;15:e0229070.
    PubMed     Abstract available


  242. YANG G, Zhang M, Zhao Y, Pan Y, et al
    HNF-4alpha inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway.
    PLoS One. 2020;15:e0230450.
    PubMed     Abstract available


  243. DIEDRICH T, Kummer S, Galante A, Drolz A, et al
    Characterization of the immune cell landscape of patients with NAFLD.
    PLoS One. 2020;15:e0230307.
    PubMed     Abstract available


  244. YEN YH, Cheng YF, Wang JH, Lin CC, et al
    Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West.
    PLoS One. 2020;15:e0230005.
    PubMed     Abstract available


  245. HEINTZ MM, McRee R, Kumar R, Baldwin WS, et al
    Gender differences in diet-induced steatotic disease in Cyp2b-null mice.
    PLoS One. 2020;15:e0229896.
    PubMed     Abstract available


  246. USON PLS JUNIOR, Tolentino FDS, Santos VM, Rother ET, et al
    The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies.
    PLoS One. 2020;15:e0230060.
    PubMed     Abstract available


  247. OKUBO H, Ando H, Ishizuka K, Kitagawa R, et al
    Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma.
    PLoS One. 2020;15:e0229772.
    PubMed     Abstract available


  248. THURING J, Kuhl CK, Barabasch A, Hitpass L, et al
    Signal changes in T2-weighted MRI of liver metastases under bevacizumab-A practical imaging biomarker?
    PLoS One. 2020;15:e0230553.
    PubMed     Abstract available


  249. RAINES MILENKOV A, Felini M, Baker E, Acharya R, et al
    Uptake of cancer screenings among a multiethnic refugee population in North Texas, 2014-2018.
    PLoS One. 2020;15:e0230675.
    PubMed     Abstract available


  250. LIU YW, Lin CC, Yong CC, Wang CC, et al
    Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center.
    PLoS One. 2020;15:e0230897.
    PubMed     Abstract available


  251. LI S, Feng X, Cao G, Wang Q, et al
    Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0230879.
    PubMed     Abstract available


  252. ZHANG F, Zhu Y, Wu S, Hou G, et al
    MLK3 is a newly identified microRNA-520b target that regulates liver cancer cell migration.
    PLoS One. 2020;15:e0230716.
    PubMed     Abstract available


  253. MIKHAIL AS, Mauda-Havakuk M, Partanen A, Karanian JW, et al
    Liver-specific 3D sectioning molds for correlating in vivo CT and MRI with tumor histopathology in woodchucks (Marmota monax).
    PLoS One. 2020;15:e0230794.
    PubMed     Abstract available


  254. ABID A, Subhani F, Kayani F, Awan S, et al
    Drug induced liver injury is associated with high mortality-A study from a tertiary care hospital in Pakistan.
    PLoS One. 2020;15:e0231398.
    PubMed     Abstract available


  255. FUCHIGAMI A, Imai Y, Uchida Y, Uchiya H, et al
    Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
    PLoS One. 2020;15:e0231427.
    PubMed     Abstract available


  256. PIEL S, Chamkha I, Dehlin AK, Ehinger JK, et al
    Cell-permeable succinate prodrugs rescue mitochondrial respiration in cellular models of acute acetaminophen overdose.
    PLoS One. 2020;15:e0231173.
    PubMed     Abstract available


  257. YU S, Wang Y, Hou J, Li W, et al
    Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival.
    PLoS One. 2020;15:e0231003.
    PubMed     Abstract available


  258. HAUKELAND JW, Smastuen MC, Palsdatter PP, Ismail M, et al
    Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway.
    PLoS One. 2020;15:e0230263.
    PubMed     Abstract available


  259. ZHANG M, Haughey M, Wang NY, Blease K, et al
    Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs.
    PLoS One. 2020;15:e0229445.
    PubMed     Abstract available


  260. KIRINO S, Tsuchiya K, Kurosaki M, Kaneko S, et al
    Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
    PLoS One. 2020;15:e0231828.
    PubMed     Abstract available


  261. LIU Y, Gao H, He YD
    A compound attributes-based predictive model for drug induced liver injury in humans.
    PLoS One. 2020;15:e0231252.
    PubMed     Abstract available


  262. WU YH, Wu CY, Cheng CY, Tsai SF, et al
    Severe hyperbilirubinemia is associated with higher risk of contrast-related acute kidney injury following contrast-enhanced computed tomography.
    PLoS One. 2020;15:e0231264.
    PubMed     Abstract available


  263. SCHOMAKER S, Potter D, Warner R, Larkindale J, et al
    Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments.
    PLoS One. 2020;15:e0229753.
    PubMed     Abstract available


  264. NAKANO D, Kawaguchi T, Iwamoto H, Hayakawa M, et al
    Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
    PLoS One. 2020;15:e0232283.
    PubMed     Abstract available


  265. SAITO K, Fukasawa M, Shirasago Y, Suzuki R, et al
    Comparative characterization of flavivirus production in two cell lines: Human hepatoma-derived Huh7.5.1-8 and African green monkey kidney-derived Vero.
    PLoS One. 2020;15:e0232274.
    PubMed     Abstract available


  266. DAVIDSON CQ, Tharmalingam S, Niccoli S, Nemec-Bakk A, et al
    Dose threshold for radiation induced fetal programming in a mouse model at 4 months of age: Hepatic expression of genes and proteins involved in glucose metabolism and glucose uptake in brown adipose tissue.
    PLoS One. 2020;15:e0231650.
    PubMed     Abstract available


  267. BENZ F, Bogen A, Praktiknjo M, Jansen C, et al
    Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis.
    PLoS One. 2020;15:e0231701.
    PubMed     Abstract available


  268. SATAPATHY SK, Gonzalez HC, Vanatta J, Dyer A, et al
    A pilot study of ex-vivo MRI-PDFF of donor livers for assessment of steatosis and predicting early graft dysfunction.
    PLoS One. 2020;15:e0232006.
    PubMed     Abstract available


  269. RAIGANI S, Carroll C, Griffith S, Pendexter C, et al
    Improvement of steatotic rat liver function with a defatting cocktail during ex situ normothermic machine perfusion is not directly related to liver fat content.
    PLoS One. 2020;15:e0232886.
    PubMed     Abstract available


  270. CAPUTO F, Dadduzio V, Tovoli F, Bertolini G, et al
    The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
    PLoS One. 2020;15:e0232449.
    PubMed     Abstract available


  271. WELBERRY C, Macdonald I, McElveen J, Parsy-Kowalska C, et al
    Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma.
    PLoS One. 2020;15:e0232247.
    PubMed     Abstract available


  272. YU Y, Bai M, Ma F, Zhang W, et al
    Regional citrate anticoagulation versus no-anticoagulation for continuous venovenous hemofiltration in patients with liver failure and increased bleeding risk: A retrospective case-control study.
    PLoS One. 2020;15:e0232516.
    PubMed     Abstract available


  273. PETZOLD G, Lasser J, Ruhl J, Bremer SCB, et al
    Diagnostic accuracy of B-Mode ultrasound and Hepatorenal Index for graduation of hepatic steatosis in patients with chronic liver disease.
    PLoS One. 2020;15:e0231044.
    PubMed     Abstract available


  274. GRIMALDI M, Palisi A, Marino C, Montoro P, et al
    NMR-based metabolomic profile of hypercholesterolemic human sera: Relationship with in vitro gene expression?
    PLoS One. 2020;15:e0231506.
    PubMed     Abstract available


  275. SI H, Genna B, Zhuang X, Wang J, et al
    DaHuangWan targets EGF signaling to inhibit the proliferation of hepatoma cells.
    PLoS One. 2020;15:e0231466.
    PubMed     Abstract available


  276. KANG JK, Heo S, Kim HP, Song SH, et al
    Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    PLoS One. 2020;15:e0232754.
    PubMed     Abstract available


  277. WANG Y, Zhou X, Zhao D, Wang X, et al
    Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes.
    PLoS One. 2020;15:e0232630.
    PubMed     Abstract available


  278. LANZA E, Masetti C, Messana G, Muglia R, et al
    Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.
    PLoS One. 2020;15:e0232371.
    PubMed     Abstract available


  279. MASUYA T, Suzuki M, Tsujimura J, Kanamori S, et al
    Ablation of Iah1, a candidate gene for diet-induced fatty liver, does not affect liver lipid accumulation in mice.
    PLoS One. 2020;15:e0233087.
    PubMed     Abstract available


  280. CHEN L, Zhang L, Wang W, Qiu W, et al
    Polysaccharides isolated from Cordyceps Sinensis contribute to the progression of NASH by modifying the gut microbiota in mice fed a high-fat diet.
    PLoS One. 2020;15:e0232972.
    PubMed     Abstract available


  281. BELAUNZARAN-ZAMUDIO PF, Caro-Vega Y, Giganti MJ, Castilho JL, et al
    Frequency of non-communicable diseases in people 50 years of age and older receiving HIV care in Latin America.
    PLoS One. 2020;15:e0233965.
    PubMed     Abstract available


  282. NGUYEN TN, Nguyen HQ, Le DH
    Unveiling prognostics biomarkers of tyrosine metabolism reprogramming in liver cancer by cross-platform gene expression analyses.
    PLoS One. 2020;15:e0229276.
    PubMed     Abstract available


  283. NAGATA S, Ozawa F, Nie M, Takeuchi S, et al
    3D culture of functional human iPSC-derived hepatocytes using a core-shell microfiber.
    PLoS One. 2020;15:e0234441.
    PubMed     Abstract available


  284. CHU YW, Chien CH, Sung MI, Chen CW, et al
    dBMHCC: A comprehensive hepatocellular carcinoma (HCC) biomarker database provides a reliable prediction system for novel HCC phosphorylated biomarkers.
    PLoS One. 2020;15:e0234084.
    PubMed     Abstract available


  285. LI C, Ge S, Zhou J, Peng J, et al
    Exploration of the effects of the CYCLOPS gene RBM17 in hepatocellular carcinoma.
    PLoS One. 2020;15:e0234062.
    PubMed     Abstract available


  286. BAEZA-RAJA B, Goodyear A, Liu X, Lam K, et al
    Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis.
    PLoS One. 2020;15:e0234038.
    PubMed     Abstract available


  287. ALBAKHEET SS, Yoon H, Shin HJ, Koh H, et al
    Bone marrow fat change in pediatric patients with non-alcoholic fatty liver disease.
    PLoS One. 2020;15:e0234096.
    PubMed     Abstract available


  288. MULEY M, Vespasiani-Gentilucci U, De Vincentis A, Santonico M, et al
    Voltammetric analysis for distinguishing portal hypertension-related from malignancy-related ascites: A proof of concept study.
    PLoS One. 2020;15:e0233350.
    PubMed     Abstract available


  289. STOCKHOFF L, Schultalbers M, Tergast TL, Hinrichs JB, et al
    Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites.
    PLoS One. 2020;15:e0235199.
    PubMed     Abstract available


  290. HAYASHI H, Yamashita YI, Okabe H, Imai K, et al
    Varied application of intercostal trans-diaphragmatic ports for laparoscopic hepatectomy.
    PLoS One. 2020;15:e0234919.
    PubMed     Abstract available


  291. CHANDRASHEKAR DS, Golonka RM, Yeoh BS, Gonzalez DJ, et al
    Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancer.
    PLoS One. 2020;15:e0234726.
    PubMed     Abstract available


  292. QIAO C, Qian H, Wang J, Zhao T, et al
    PD173074 blocks G1/S transition via CUL3-mediated ubiquitin protease in HepG2 and Hep3B cells.
    PLoS One. 2020;15:e0234708.
    PubMed     Abstract available


  293. UESATO Y, Sasahira N, Ozaka M, Sasaki T, et al
    Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis.
    PLoS One. 2020;15:e0235623.
    PubMed     Abstract available


  294. KOCH C, Bette T, Waidmann O, Filmann N, et al
    AFP ratio predicts HCC recurrence after liver transplantation.
    PLoS One. 2020;15:e0235576.
    PubMed     Abstract available


  295. COHEN AM, Chamberlin S, Deloughery T, Nguyen M, et al
    Detecting rare diseases in electronic health records using machine learning and knowledge engineering: Case study of acute hepatic porphyria.
    PLoS One. 2020;15:e0235574.
    PubMed     Abstract available


  296. NICHOLS PH, Pan Y, May B, Pavlicova M, et al
    Effect of TSH on Non-Alcoholic Fatty Liver Disease (NAFLD) independent of obesity in children of predominantly Hispanic/Latino ancestry by causal mediation analysis.
    PLoS One. 2020;15:e0234985.
    PubMed     Abstract available


  297. SZUCS A, Paku S, Sebestyen E, Nagy P, et al
    Postnatal, ontogenic liver growth accomplished by biliary/oval cell proliferation and differentiation.
    PLoS One. 2020;15:e0233736.
    PubMed     Abstract available


  298. FORTEA JI, Puerto M, Fernandez-Mena C, Asensio I, et al
    Sevoflurane versus ketamine+diazepam anesthesia for assessing systemic and hepatic hemodynamics in rats with non-cirrhotic portal hypertension.
    PLoS One. 2020;15:e0233778.
    PubMed     Abstract available


  299. NUDISCHER R, Renggli K, Hierlemann A, Roth AB, et al
    Characterization of a long-term mouse primary liver 3D tissue model recapitulating innate-immune responses and drug-induced liver toxicity.
    PLoS One. 2020;15:e0235745.
    PubMed     Abstract available


  300. WANG J, Shen P, Liao S, Duan L, et al
    Selenoprotein P inhibits cell proliferation and ROX production in HCC cells.
    PLoS One. 2020;15:e0236491.
    PubMed     Abstract available


  301. KRISS M, Golden-Mason L, Kaplan J, Mirshahi F, et al
    Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development.
    PLoS One. 2020;15:e0236353.
    PubMed     Abstract available


  302. GOURRONC FA, Markan KR, Kulhankova K, Zhu Z, et al
    Pdgfralpha-Cre mediated knockout of the aryl hydrocarbon receptor protects mice from high-fat diet induced obesity and hepatic steatosis.
    PLoS One. 2020;15:e0236741.
    PubMed     Abstract available


  303. DIESINGER T, Buko V, Lautwein A, Dvorsky R, et al
    Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis.
    PLoS One. 2020;15:e0235990.
    PubMed     Abstract available


  304. OKUSHIN K, Tsutsumi T, Ikeuchi K, Kado A, et al
    Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet.
    PLoS One. 2020;15:e0234750.
    PubMed     Abstract available


  305. PELTONEN R, Gramkow MH, Dehlendorff C, Osterlund PJ, et al
    Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.
    PLoS One. 2020;15:e0236569.
    PubMed     Abstract available


  306. YASUI D, Yamane A, Itoh H, Kobayashi M, et al
    In vivo evaluation of a monodisperse solid-in-oil-in-water miriplatin/ lipiodol emulsion in transcatheter arterial chemoembolization using a rabbit VX2 tumor model.
    PLoS One. 2020;15:e0222553.
    PubMed     Abstract available


  307. STEMMER A, Shadmi R, Bregman-Amitai O, Chettrit D, et al
    Using machine learning algorithms to review computed tomography scans and assess risk for cardiovascular disease: Retrospective analysis from the National Lung Screening Trial (NLST).
    PLoS One. 2020;15:e0236021.
    PubMed     Abstract available


  308. SHEN Q, Hu G, Wu J, Lv L, et al
    A new clinical prognostic nomogram for liver cancer based on immune score.
    PLoS One. 2020;15:e0236622.
    PubMed     Abstract available


  309. YOO JJ, Lim YS, Kim MS, Lee B, et al
    Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer.
    PLoS One. 2020;15:e0236506.
    PubMed     Abstract available


  310. RASHIDI-ALAVIJEH J, Ceylan AS, Wedemeyer H, Kleefisch M, et al
    Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis.
    PLoS One. 2020;15:e0236528.
    PubMed     Abstract available


  311. SERPER M, Vujkovic M, Kaplan DE, Carr RM, et al
    Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program.
    PLoS One. 2020;15:e0237430.
    PubMed     Abstract available


  312. FUKUDA H, Sato D, Moriwaki K, Ishida H, et al
    Differences in healthcare expenditure estimates according to statistical approach: A nationwide claims database study on patients with hepatocellular carcinoma.
    PLoS One. 2020;15:e0237316.
    PubMed     Abstract available


  313. HAL WA, Straza MW, Chen X, Mickevicius N, et al
    Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac.
    PLoS One. 2020;15:e0236570.
    PubMed     Abstract available


  314. CHEN K, Sng WK, Quah JH, Liu J, et al
    Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
    PLoS One. 2020;15:e0236977.
    PubMed     Abstract available


  315. FORLANO R, Mullish BH, Mukherjee SK, Nathwani R, et al
    In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19.
    PLoS One. 2020;15:e0240400.
    PubMed     Abstract available


  316. SOGABE M, Okahisa T, Kurihara T, Takehara M, et al
    Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome.
    PLoS One. 2020;15:e0238388.
    PubMed     Abstract available


  317. TAMAI Y, Iwasa M, Eguchi A, Shigefuku R, et al
    Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma.
    PLoS One. 2020;15:e0237370.
    PubMed     Abstract available


  318. CHANG TT, Ho CH
    Plasma proteome atlas for differentiating tumor stage and post-surgical prognosis of hepatocellular carcinoma and cholangiocarcinoma.
    PLoS One. 2020;15:e0238251.
    PubMed     Abstract available


  319. LIRA MMP, de Medeiros Filho JEM, Baccin Martins VJ, da Silva G, et al
    Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study.
    PLoS One. 2020;15:e0237360.
    PubMed     Abstract available


  320. RONDA OAHO, van de Heijning BJM, de Bruin A, Thomas RE, et al
    Spontaneous liver disease in wild-type C57BL/6JOlaHsd mice fed semisynthetic diet.
    PLoS One. 2020;15:e0232069.
    PubMed     Abstract available


  321. LEE J, Vali Y, Boursier J, Duffin K, et al
    Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0238717.
    PubMed     Abstract available


  322. ROGAL SS, Yakovchenko V, Gonzalez R, Park A, et al
    Characterizing patient-reported outcomes in veterans with cirrhosis.
    PLoS One. 2020;15:e0238712.
    PubMed     Abstract available


  323. HAYASHI M, Abe K, Fujita M, Takahashi A, et al
    Association between serum ficolin-1 level and disease progression in primary biliary cholangitis.
    PLoS One. 2020;15:e0238300.
    PubMed     Abstract available


  324. RAJCIC D, Brandt A, Jin CJ, Sanchez V, et al
    Exchanging dietary fat source with extra virgin olive oil does not prevent progression of diet-induced non-alcoholic fatty liver disease and insulin resistance.
    PLoS One. 2020;15:e0237946.
    PubMed     Abstract available


  325. STRADOMSKA TJ, Syczewska M, Jamroz E, Pleskaczynska A, et al
    Serum very long-chain fatty acids (VLCFA) levels as predictive biomarkers of diseases severity and probability of survival in peroxisomal disorders.
    PLoS One. 2020;15:e0238796.
    PubMed     Abstract available


  326. CORREA F, Hidalgo C, Stoore C, Jimenez M, et al
    Cattle co-infection of Echinococcus granulosus and Fasciola hepatica results in a different systemic cytokine profile than single parasite infection.
    PLoS One. 2020;15:e0238909.
    PubMed     Abstract available


  327. MAUNG K, Ramalingam S, Chaudhry M, Ren Y, et al
    Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality.
    PLoS One. 2020;15:e0238824.
    PubMed     Abstract available


  328. GRIFFETT K, Bedia-Diaz G, Elgendy B, Burris TP, et al
    REV-ERB agonism improves liver pathology in a mouse model of NASH.
    PLoS One. 2020;15:e0236000.
    PubMed     Abstract available


  329. SANTOIEMMA PP, Dakwar O, Angarone MP
    A retrospective analysis of cases of Spontaneous Bacterial Peritonitis in cirrhosis patients.
    PLoS One. 2020;15:e0239470.
    PubMed     Abstract available


  330. LOOSEN SH, Wirtz TH, Roy S, Vucur M, et al
    Circulating levels of microRNA193a-5p predict outcome in early stage hepatocellular carcinoma.
    PLoS One. 2020;15:e0239386.
    PubMed     Abstract available


  331. WANG S, Toy M, Hang Pham TT, So S, et al
    Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019.
    PLoS One. 2020;15:e0239393.
    PubMed     Abstract available


  332. KANEKO S, Kurosaki M, Nagata K, Taki R, et al
    Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity.
    PLoS One. 2020;15:e0241663.
    PubMed     Abstract available


  333. PENG J, Zhou M, Chen C, Xie X, et al
    Identification of exacerbation risk in patients with liver dysfunction using machine learning algorithms.
    PLoS One. 2020;15:e0239266.
    PubMed     Abstract available


  334. CHOI JW, Lee JM, Lee DH, Yoon JH, et al
    Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study.
    PLoS One. 2020;15:e0239733.
    PubMed     Abstract available


  335. REY R M, Delgado AF, De Zubiria A, Pinto R, et al
    Prevalence and short-term outcome of hepatorenal syndrome: A 9-year experience in a high-complexity hospital in Colombia.
    PLoS One. 2020;15:e0239834.
    PubMed     Abstract available


  336. RIEXINGER A, Laun FB, Bickelhaupt S, Seuss H, et al
    On the dependence of the cardiac motion artifact on the breathing cycle in liver diffusion-weighted imaging.
    PLoS One. 2020;15:e0239743.
    PubMed     Abstract available


  337. MANN JP, Carter P, Armstrong MJ, Abdelaziz HK, et al
    Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors.
    PLoS One. 2020;15:e0241357.
    PubMed     Abstract available


  338. GOODSON ML, Knotts TA, Campbell EL, Snyder CA, et al
    Specific ablation of the NCoR corepressor delta splice variant reveals alternative RNA splicing as a key regulator of hepatic metabolism.
    PLoS One. 2020;15:e0241238.
    PubMed     Abstract available


  339. KIM MC, Lee JI, Kim JH, Kim HJ, et al
    Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    PLoS One. 2020;15:e0240195.
    PubMed     Abstract available


  340. SORINO P, Caruso MG, Misciagna G, Bonfiglio C, et al
    Selecting the best machine learning algorithm to support the diagnosis of Non-Alcoholic Fatty Liver Disease: A meta learner study.
    PLoS One. 2020;15:e0240867.
    PubMed     Abstract available


  341. HASSAN S, Peluso J, Chalhoub S, Idoux Gillet Y, et al
    Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1alpha and MDR1.
    PLoS One. 2020;15:e0240676.
    PubMed     Abstract available


  342. LIN YJ, Lin CN, Sedghi T, Hsu SH, et al
    Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan.
    PLoS One. 2020;15:e0240542.
    PubMed     Abstract available


  343. ZHANG L, Yuan Q, Xu Y, Wang W, et al
    Comparative clinical outcomes of robot-assisted liver resection versus laparoscopic liver resection: A meta-analysis.
    PLoS One. 2020;15:e0240593.
    PubMed     Abstract available


  344. CHURCH RJ, Schomaker SJ, Eaddy JS, Boucher GG, et al
    Glutamate dehydrogenase as a biomarker for mitotoxicity; insights from furosemide hepatotoxicity in the mouse.
    PLoS One. 2020;15:e0240562.
    PubMed     Abstract available


  345. YAN B, Luo J, Kaltenmeier C, Du Q, et al
    Interferon Regulatory Factor-1 (IRF1) activates autophagy to promote liver ischemia/reperfusion injury by inhibiting beta-catenin in mice.
    PLoS One. 2020;15:e0239119.
    PubMed     Abstract available


  346. GRANATA V, Fusco R, Avallone A, Cassata A, et al
    Abbreviated MRI protocol for colorectal liver metastases: How the radiologist could work in pre surgical setting.
    PLoS One. 2020;15:e0241431.
    PubMed     Abstract available


  347. BAUMLER W, Schicho A, Schaible J, Verloh N, et al
    Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors.
    PLoS One. 2020;15:e0242093.
    PubMed     Abstract available


  348. ZHAO Y, Zhu C, Chang Q, Peng P, et al
    MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7.
    PLoS One. 2020;15:e0242179.
    PubMed     Abstract available


  349. GUO B, Tan X, Cen H
    EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma.
    PLoS One. 2020;15:e0242191.
    PubMed     Abstract available


  350. FENG L, Dong K, Zhang X, Ma B, et al
    Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.
    PLoS One. 2020;15:e0242164.
    PubMed     Abstract available


  351. CHEN HY, Lu SN, Hung CH, Wang JH, et al
    Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation.
    PLoS One. 2020;15:e0242113.
    PubMed     Abstract available


  352. GALIERO R, Pafundi PC, Simeon V, Rinaldi L, et al
    Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study.
    PLoS One. 2020;15:e0243700.
    PubMed     Abstract available


  353. VISARIA A, Pai S, Fayngersh A, Kothari N, et al
    Association between alanine aminotransferase within the normal range and all-cause and cause-specific mortality: A nationwide cohort study.
    PLoS One. 2020;15:e0242431.
    PubMed     Abstract available


  354. SAKAMAKI A, Yokoyama K, Koyama K, Morita S, et al
    Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis.
    PLoS One. 2020;15:e0242582.
    PubMed     Abstract available


  355. PARK JH, Chung YE, Seo N, Choi JY, et al
    Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Diagnostic performance of category-adjusted LR-5 using modified criteria.
    PLoS One. 2020;15:e0242344.
    PubMed     Abstract available


  356. CHOI J, Kim SH, Han S, Lee D, et al
    A simple and clinically applicable model to predict liver-related morbidity after hepatic resection for hepatocellular carcinoma.
    PLoS One. 2020;15:e0241808.
    PubMed     Abstract available


  357. CHIU TJ, Chen YJ, Kuo FY, Chen YY, et al
    Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma.
    PLoS One. 2020;15:e0240791.
    PubMed     Abstract available


  358. MOLE DJ, Fallowfield JA, Sherif AE, Kendall T, et al
    Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer.
    PLoS One. 2020;15:e0238568.
    PubMed     Abstract available


  359. LEUNG CCT, Wong CKC
    Effects of stanniocalcin-1 overexpressing hepatocellular carcinoma cells on macrophage migration.
    PLoS One. 2020;15:e0241932.
    PubMed     Abstract available


  360. PALLADINI G, Ferrigno A, Di Pasqua LG, Berardo C, et al
    Associations between serum trace elements and inflammation in two animal models of nonalcoholic fatty liver disease.
    PLoS One. 2020;15:e0243179.
    PubMed     Abstract available


  361. LUONG XG, Stevens SK, Jekle A, Lin TI, et al
    Regulation of gene transcription by thyroid hormone receptor beta agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
    PLoS One. 2020;15:e0240338.
    PubMed     Abstract available


  362. HIROSE S, Matsumoto K, Tatemichi M, Tsuruya K, et al
    Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients.
    PLoS One. 2020;15:e0241770.
    PubMed     Abstract available


  363. XIAO C, Fu X, Wang Y, Liu H, et al
    Transferrin receptor regulates malignancies and the stemness of hepatocellular carcinoma-derived cancer stem-like cells by affecting iron accumulation.
    PLoS One. 2020;15:e0243812.
    PubMed     Abstract available


  364. ADHYAPOK P, Fu X, Sluka JP, Clendenon SG, et al
    A computational model of liver tissue damage and repair.
    PLoS One. 2020;15:e0243451.
    PubMed     Abstract available


  365. BRAUNWARTH E, Rumpf B, Primavesi F, Pereyra D, et al
    Sex differences in disease presentation, surgical and oncological outcome of liver resection for primary and metastatic liver tumors-A retrospective multicenter study.
    PLoS One. 2020;15:e0243539.
    PubMed     Abstract available


  366. LEE S, Kim JH, Moon H, Lee HJ, et al
    Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study.
    PLoS One. 2020;15:e0243815.
    PubMed     Abstract available


  367. BAYOUMI A, Jalil I, Metwally M, Adams LA, et al
    Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.
    PLoS One. 2020;15:e0243590.
    PubMed     Abstract available


  368. BAE CR, Zhang H, Kwon YG
    The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
    PLoS One. 2020;15:e0243497.
    PubMed     Abstract available


  369. SOHN W, Ham CB, Kim NH, Kim HJ, et al
    Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    PLoS One. 2020;15:e0243780.
    PubMed     Abstract available


  370. YEN FS, Lai JN, Wei JC, Chiu LT, et al
    Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
    PLoS One. 2020;15:e0243783.
    PubMed     Abstract available


  371. YUAN Y, Naito H, Kitamori K, Hashimoto S, et al
    The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension.
    PLoS One. 2020;15:e0243846.
    PubMed     Abstract available


  372. WANG G, Wang Q, Bai J, Li G, et al
    RYGB increases postprandial gastric nesfatin-1 and rapid relieves NAFLD via gastric nerve detachment.
    PLoS One. 2020;15:e0243640.
    PubMed     Abstract available


  373. LIU L, Liu C, Zhao M, Zhang Q, et al
    The pharmacodynamic and differential gene expression analysis of PPAR alpha/delta agonist GFT505 in CDAHFD-induced NASH model.
    PLoS One. 2020;15:e0243911.
    PubMed     Abstract available


  374. MANJARIN R, Maj MA, La Frano MR, Glanz H, et al
    %polynova_2way: A SAS macro for implementation of mixed models for metabolomics data.
    PLoS One. 2020;15:e0244013.
    PubMed     Abstract available


  375. HSIEH MH, Kao TY, Hsieh TH, Kao CC, et al
    Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
    PLoS One. 2020;15:e0244293.
    PubMed     Abstract available


  376. WEISSINGER M, Vogel J, Kupferschlager J, Dittmann H, et al
    Correlation of C-arm CT acquired parenchymal blood volume (PBV) with 99mTc-macroaggregated albumin (MAA) SPECT/CT for radioembolization work-up.
    PLoS One. 2020;15:e0244235.
    PubMed     Abstract available


  377. RYU H, Kim JH, Lee S, Han JK, et al
    Therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma using contrast-enhanced ultrasound: Focusing on inter-scanner, and inter-operator reproducibility.
    PLoS One. 2020;15:e0244304.
    PubMed     Abstract available


  378. SEMMLER G, Bachmayer S, Wernly S, Wernly B, et al
    Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease.
    PLoS One. 2020;15:e0244514.
    PubMed     Abstract available


  379. BORTOLAMI M, Comparato A, Benna C, Errico A, et al
    Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and "normal" liver tissues.
    PLoS One. 2020;15:e0244356.
    PubMed     Abstract available


  380. HAYASHI T, Shibata M, Oe S, Miyagawa K, et al
    C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.
    PLoS One. 2020;15:e0244370.
    PubMed     Abstract available


  381. THULUVATH PJ, Amjad W, Zhang T
    Liver transplant waitlist removal, transplantation rates and post-transplant survival in Hispanics.
    PLoS One. 2020;15:e0244744.
    PubMed     Abstract available


  382. PILLING D, Karhadkar TR, Gomer RH
    A CD209 ligand and a sialidase inhibitor differentially modulate adipose tissue and liver macrophage populations and steatosis in mice on the Methionine and Choline-Deficient (MCD) diet.
    PLoS One. 2020;15:e0244762.
    PubMed     Abstract available


    January 2019
  383. HOWELL AK, McCann CM, Wickstead F, Williams DJL, et al
    Co-infection of cattle with Fasciola hepatica or F. gigantica and Mycobacterium bovis: A systematic review.
    PLoS One. 2019;14:e0226300.
    PubMed     Abstract available


  384. SUDJARITRUK T, Bunupuradah T, Aurpibul L, Kosalaraksa P, et al
    Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy.
    PLoS One. 2019;14:e0226375.
    PubMed     Abstract available


  385. ERKAN B, Meier J, Clark TJ, Kaplan J, et al
    Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC.
    PLoS One. 2019;14:e0226291.
    PubMed     Abstract available


  386. ABBASS MA, Ahmad SA, Mahalingam N, Krothapalli KS, et al
    In vivo ultrasound thermal ablation control using echo decorrelation imaging in rabbit liver and VX2 tumor.
    PLoS One. 2019;14:e0226001.
    PubMed     Abstract available


  387. SU RC, Lad A, Breidenbach JD, Blomquist TM, et al
    Hyperglycemia induces key genetic and phenotypic changes in human liver epithelial HepG2 cells which parallel the Leprdb/J mouse model of non-alcoholic fatty liver disease (NAFLD).
    PLoS One. 2019;14:e0225604.
    PubMed     Abstract available


  388. ZHONG GC, Liu S, Wu YL, Xia M, et al
    ABO blood group and risk of newly diagnosed nonalcoholic fatty liver disease: A case-control study in Han Chinese population.
    PLoS One. 2019;14:e0225792.
    PubMed     Abstract available


  389. SCOTT C, Stokes R, Cha KM, Clouston A, et al
    Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis.
    PLoS One. 2019;14:e0225332.
    PubMed     Abstract available


  390. WELDEAREGAY KT, Gebrekidan MG, Gezahegne AA
    Health impact of hepatic-venous-occlusive disease in a small town in Ethiopia-Case study from Tahtay koraro district in Tigray region, 2017.
    PLoS One. 2019;14:e0224659.
    PubMed     Abstract available


  391. SENDRA L, Herrero MJ, Montalva EM, Noguera I, et al
    Efficacy of interleukin 10 gene hydrofection in pig liver vascular isolated 'in vivo' by surgical procedure with interest in liver transplantation.
    PLoS One. 2019;14:e0224568.
    PubMed     Abstract available


  392. YANG S, Kwak S, Lee JH, Kang S, et al
    Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population.
    PLoS One. 2019;14:e0224626.
    PubMed     Abstract available


  393. BUCHER JN, Koenig M, Schoenberg MB, Crispin A, et al
    Liver transplantation in patients with a history of migration-A German single center comparative analysis.
    PLoS One. 2019;14:e0224116.
    PubMed     Abstract available


  394. BAJAJ JS, Fan S, Thacker LR, Fagan A, et al
    Serum and urinary metabolomics and outcomes in cirrhosis.
    PLoS One. 2019;14:e0223061.
    PubMed     Abstract available


  395. ISHIKAWA T, Sasaki R, Nishimura T, Aibe Y, et al
    A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification.
    PLoS One. 2019;14:e0223153.
    PubMed     Abstract available


  396. LIU Y, Liu X, Wang Y, Yi C, et al
    Protective effect of lactobacillus plantarum on alcoholic liver injury and regulating of keap-Nrf2-ARE signaling pathway in zebrafish larvae.
    PLoS One. 2019;14:e0222339.
    PubMed     Abstract available


  397. LEVICK C, Phillips-Hughes J, Collier J, Banerjee R, et al
    Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study.
    PLoS One. 2019;14:e0221066.
    PubMed     Abstract available


  398. MIN-DEBARTOLO J, Schlerman F, Akare S, Wang J, et al
    Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    PLoS One. 2019;14:e0226854.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: